Madrigal Pharmaceuticals (MDGL) Change in Cash (2010 - 2026)

Madrigal Pharmaceuticals (MDGL) has reported Change in Cash for 17 consecutive years, with $60.7 million the latest figure, recorded in Q2 2026.

• In Q2 2026, Change in Cash rose 2282.92% year-over-year to $60.7 million; the TTM figure through Jun 2026 stood at $101.7 million (up 132.97% YoY), while the FY2025 annual figure was $98.8 million, up 1835.03% from the prior year.
• Change in Cash improved to $60.7 million in Q2 2026 per MDGL's latest filing, from $28.4 million in the prior quarter.
• Across five years, Change in Cash topped out at $522.6 million in Q1 2024 and bottomed at -$261.9 million in Q3 2024.
• Historically, Change in Cash has averaged $14.3 million across 5 years, with a median of $6.0 million in 2022.
• Annual changes were most pronounced in 2023 — Change in Cash plunged 3729.49% — and 2026, when it soared 2282.92%.
• Madrigal Pharmaceuticals' Change in Cash stood at $272.2 million in 2022, then sank by 86.09% to $37.9 million in 2023, then tumbled by 450.41% to -$132.7 million in 2024, then advanced by 26.95% to -$96.9 million in 2025, then surged by 162.63% to $60.7 million in 2026.
• Business Quant data shows MDGL's Change in Cash at $60.7 million in Q2 2026, $28.4 million in Q1 2026, and -$96.9 million in Q4 2025.